These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 26986803)

  • 1. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
    Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
    Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.
    Paton NI; Stöhr W; Arenas-Pinto A; Fisher M; Williams I; Johnson M; Orkin C; Chen F; Lee V; Winston A; Gompels M; Fox J; Scott K; Dunn DT;
    Lancet HIV; 2015 Oct; 2(10):e417-26. PubMed ID: 26423649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
    Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.
    Oddershede L; Walker S; Stöhr W; Dunn DT; Arenas-Pinto A; Paton NI; Sculpher M;
    Pharmacoeconomics; 2016 Aug; 34(8):795-804. PubMed ID: 26966125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
    Paton NI; Stöhr W; Arenas-Pinto A; Clarke A; Williams I; Johnson M; Orkin C; Chen F; Lee V; Winston A; Gompels M; Fox J; Sanders K; Dunn DT;
    EClinicalMedicine; 2024 Mar; 69():102457. PubMed ID: 38361989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
    Gilks CF; Walker AS; Dunn DT; Gibb DM; Kikaire B; Reid A; Musana H; Mambule I; Kasirye R; Robertson V; Ssali F; Spyer M; Pillay D; Yirrell D; Kaleebu P;
    Antivir Ther; 2012; 17(7):1363-73. PubMed ID: 22814125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.
    Arenas-Pinto A; Stöhr W; Jäger HR; Haddow L; Clarke A; Johnson M; Chen F; Winston A; Godi C; Thust S; Trombin R; Cairns J; Solanky BS; Golay X; Paton NI;
    Clin Infect Dis; 2016 Jul; 63(2):257-64. PubMed ID: 27143662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
    Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
    Galli L; Spagnuolo V; Bigoloni A; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Borderi M; Gibellini D; Caramatti G; Lazzarin A; Castagna A;
    J Antimicrob Chemother; 2016 Jun; 71(6):1637-42. PubMed ID: 26945711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
    Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy.
    Reina E; San Miguel R; Larrea N; Garcia P; Napal V
    Int J Clin Pharm; 2012 Dec; 34(6):911-6. PubMed ID: 23007692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.
    Stöhr W; Dunn DT; Arenas-Pinto A; Orkin C; Clarke A; Williams I; Johnson M; Beeching NJ; Wilkins E; Sanders K; Paton NI;
    AIDS; 2016 Nov; 30(17):2617-2624. PubMed ID: 27456983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
    Gianotti N; Cozzi-Lepri A; Antinori A; Castagna A; De Luca A; Celesia BM; Galli M; Mussini C; Pinnetti C; Spagnuolo V; d'Arminio Monforte A; Ceccherini-Silberstein F; Andreoni M;
    PLoS One; 2017; 12(2):e0171611. PubMed ID: 28192453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.
    Dunn DT; Stöhr W; Arenas-Pinto A; Tostevin A; Mbisa JL; Paton NI;
    J Clin Virol; 2018 Apr; 101():63-65. PubMed ID: 29428459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.